Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

Completed · Phase 1

Conditions studied: HIV Infections

In brief

HIV-1-infected patients who have been treated with anti-HIV drugs for a long time may have weakened immune responses to HIV. The DNA-based vaccine in this study is designed to boost the immune system's responses against many HIV-1 proteins. The main purposes of this study are to test the safety of this HIV vaccine (EP HIV-1090) and to test whether the vaccine can stimulate immune system responses in people who have HIV-1 infection.

Key facts

Study ID

NCT00052182

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

40

Starts

2002-10-01

Last updated by the study team

2007-10-23

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented HIV-1 infection
• Taking HAART for 6 months or longer and on stable HAART for at least 4 weeks
• Plasma HIV-1 viral load of less than 400 copies/ml for at least 6 months prior to study entry
• CD4 count of 350 cells/mm3 or more within 30 days of entry

You may not qualify if…

• Immunomodulatory agents
• Prior receipt of experimental HIV vaccines in the 5 years prior to study entry
• Hepatitis B surface antigen or hepatitis C virus antibody positive

Where it is running

• University of Colorado, Health Science Center — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.